newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - SAB BIOTHERAPEUTICS INC

  • Financial Performance:

    • Company is currently in the clinical stage with no reported revenue, earnings, or cash flow metrics as it is pre-commercial.
    • No specific debt figures, deferred revenue, or profit margins disclosed; focus remains on R&D funding through Phase 1 and Phase 2b trials.
    • Sanofi's prior $3 billion acquisition of competitor T-Zield mentioned as a benchmark for market valuation potential in the T1D space.
  • Guidance and Future Outlook:

    • Enrollment for the pivotal SAVEGUARD (Phase 2b) study is expected to complete this month.
    • Top-line data release for SAVEGUARD is targeted for 2027.
    • The Prize Study (Phase 3 investigator-initiated) expects first patient enrollment this quarter; timeline depends on site enrollment pace.
    • Long-term goal is to expand the treatment window from the current 100-day post-diagnosis limit to up to two years if Prize Study data supports efficacy in later cohorts.
  • Business Segments and Product Lines:

    • Core focus is Type 1 Diabetes (T1D) treatment using SAB-142, a proprietary human antithymocyte immunoglobulin (human anti-thymosine IgG).
    • SAVEGUARD study is a pivotal trial designed to test C-peptide preservation (primary endpoint) and glycemic control metrics like HbA1c, insulin use, and time in range.
    • Prize Study involves a Phase 3 expansion into two new cohorts: patients diagnosed 100–365 days post-onset and 365 days–2 years post-onset.
    • Drug profile differentiates from competitors via a 2-day dosing regimen (vs. 12 days for T-Zield) and redosability for life-long therapy.
  • Market and Competitive Landscape:

    • T-Zield recently received FDA approval for Stage 3 T1D, creating a paradigm shift toward immunomodulation and organ preservation rather than just glucose management.
    • First commercial quarter for T-Zield in Stage 3 reached approximately $47 million, up from $25 million in Stage 2, indicating strong market adoption despite dosing burdens.
    • T-Zield is rabbit-derived, highly immunogenic, non-redosable, and limited to 12-day infusions; SAB-142 is fully human, non-immunogenic, redosable, and requires only 2 days.
    • Total Addressable Market (TAM) for T1D immunomodulation is estimated at $20 billion, with interest growing as the space is reclassified from insulin-centric to autoimmune disease treatment.
  • Risks and Challenges:

    • Potential regulatory risk exists where the drug might achieve accelerated approval based solely on C-peptide preservation without hitting secondary clinical endpoints (HbA1c).
    • Clinical trial execution risks in the Prize Study due to reliance on academic investigators rather than internal company control.
    • Competitive pressure from T-Zield's established first-mover advantage and regulatory precedent, though SAB-142 leverages a "second-comer" advantage with superior product attributes.
  • Management Commentary and Tone:

    • Management expressed high confidence in the SAVEGUARD study design, citing power calculations based on historical data from the reference drug thymoglobulin (Sanofi).
    • Tone was optimistic and educational, emphasizing the underappreciated nature of the T1D autoimmune treatment market.
    • Executives highlighted the "heavy lifting" done by T-Zield in educating physicians, positioning SAB-142 to capitalize on a newly aware medical community.
  • Analyst Questions and Answers:

    • Differentiation: Confirmed SAB-142's superiority over T-Zield regarding dosing frequency (2 vs. 12 days), redosability, and lack of serum sickness due to human origin.
    • Regulatory Path: Clarified that while C-peptide is sufficient for accelerated approval (precedent set by T-Zield), the company expects to hit HbA1c for full approval.
    • Safety Profile: Phase 1 data showed manageable adverse events (headaches, Grade 1 CRS/flu-like symptoms) that are reversible within a day with steroids.
    • Market Size: Discussed the transition of T-Zield sales from Stage 2 to Stage 3, noting the Stage 3 market is 10x larger than Stage 2.
  • Other Key Points:

    • SAB-142's mechanism mirrors thymoglobulin but avoids its immunogenicity issues, allowing for the same efficacy profile with a better safety and dosing profile.
    • The industry is shifting from managing symptoms (insulin/glucose) to disease modification (preserving endogenous insulin production).
    • The Prize Study is funded by Breakthrough T1D and led by key opinion leaders including Dr. Mike Haller and Dr. Chantal Mathieu.
Company
SAB BIOTHERAPEUTICS INC
Keywords
SAB BIOTHERAPEUTICS INC